Clinical Trial Update: A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase III trial evaluating maintenance lurbinectedin in combination with atezolizumab versus atezolizumab alone in extensive-stage small-cell lung cancer; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Tecentriq (atezolizumab) (atezolizumab)
• Zepzelca (lurbinectedin) (Lurbinectedin)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Small-Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-12-29